MENU
NEWSLETTERS
MENU
SECTIONS
OTHER
CLASSIFIEDS
CONTACT US / FAQ
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Junshi Biosciences

News headline image
Toripalimab Presents Long-Term Survival Benefits as 1st-line Treatment for Advanced Nasopharyngeal Carcinoma and Esophageal Squamous Cell Carcinoma Patients
From Junshi Biosciences
Via GlobeNewswire
News headline image
Junshi Biosciences Announces Acceptance of the NDA for Roconkibart (IL-17A) for the Treatment of Moderate to Severe Plaque Psoriasis
From Junshi Biosciences
Via GlobeNewswire
News headline image
Junshi Biosciences Announces Primary Endpoints Met in JS001sc’s Phase 3 Study for the 1ST-line Treatment of NSQ-NSCLC
From Junshi Biosciences
Via GlobeNewswire
News headline image
Junshi Biosciences Announces FDA’s Approval of IND Application for Phase 2/3 Clinical Study of JS207 for the Neoadjuvant Treatment of NSCLC Patients
From Junshi Biosciences
Via GlobeNewswire
News headline image
Junshi Biosciences Announces the Phase 3 Study of JS005 (IL-17A) for the Treatment of Moderate to Severe Plaque Psoriasis Met Primary Endpoints
From Junshi Biosciences
Via GlobeNewswire
News headline image
Junshi Biosciences Announces 2025 Interim Financial Results and Provides Corporate Updates
From Junshi Biosciences
Via GlobeNewswire
News headline image
Junshi Biosciences Announces the Acceptance of the sNDA for Toripalimab as the 1st-line Treatment of HER2-expressing Urothelial Carcinoma
From Junshi Biosciences
Via GlobeNewswire
News headline image
Junshi Biosciences Announces Ongericimab’s sNDA Approval in China
From Junshi Biosciences
Via GlobeNewswire
News headline image
Junshi Biosciences Announces the sNDA Approval of Toripalimab for the 1st-line Treatment of Melanoma
From Junshi Biosciences
Via GlobeNewswire
News headline image
Junshi Biosciences Announces 2024 Full Year Financial Results and Provides Corporate Updates
From Junshi Biosciences
Via GlobeNewswire
News headline image
Junshi Biosciences Announces Toripalimab’s Approval in Singapore
From Junshi Biosciences
Via GlobeNewswire
News headline image
Junshi Biosciences Announces Approval of sNDA for Toripalimab in Combination with Bevacizumab for 1st-line Treatment of Advanced Hepatocellular Carcinoma
From Junshi Biosciences
Via GlobeNewswire
News headline image
Junshi Biosciences Announces Commercialization Partnership with LEO Pharma for Toripalimab in Europe
From Junshi Biosciences
Via GlobeNewswire
News headline image
Junshi Biosciences Announces Toripalimab’s Approval in Australia
From Junshi Biosciences
Via GlobeNewswire
News headline image
Junshi Biosciences Announces UK MHRA Approval for Marketing of Toripalimab
From Junshi Biosciences
Via GlobeNewswire
News headline image
Junshi Biosciences Announces Toripalimab Obtained Approval for Marketing in India and China’s Hong Kong SAR
From Junshi Biosciences
Via GlobeNewswire
News headline image
Junshi Biosciences Announces European Commission Approval for Marketing of Toripalimab
From Junshi Biosciences
Via GlobeNewswire
News headline image
Junshi Biosciences Announces 2024 Interim Financial Results and Provides Corporate Updates
From Junshi Biosciences
Via GlobeNewswire
News headline image
Junshi Biosciences Announces Acceptance of Supplemental New Drug Application for Toripalimab as First-Line Treatment of Unresectable/Metastatic Melanoma
From Junshi Biosciences
Via GlobeNewswire
News headline image
Junshi Biosciences Announces Positive Opinion from the European Medicines Agency’s CHMP For Toripalimab
From Junshi Biosciences
Via GlobeNewswire
News headline image
Junshi Biosciences Announces the Acceptance of the Supplemental New Drug Application for Toripalimab Combined with Bevacizumab for the First-Line Treatment of Advanced Hepatocellular Carcinoma
From Junshi Biosciences
Via GlobeNewswire
News headline image
Junshi Biosciences Announces Approval of the sNDA for Toripalimab for the 1st-Line Treatment of Advanced TNBC
From Junshi Biosciences
Via GlobeNewswire
News headline image
Junshi Biosciences Announces Approval of the sNDA for Toripalimab for the 1st-Line Treatment of Small Cell Lung Cancer
From Junshi Biosciences
Via GlobeNewswire
News headline image
Junshi Biosciences Announces Phase 3 Study of Toripalimab Combined with Bevacizumab for the First-line Treatment of Advanced Hepatocellular Carcinoma Meets Primary Endpoint
From Junshi Biosciences
Via GlobeNewswire
News headline image
Junshi Biosciences Announces NDA Acceptance in Hong Kong for Toripalimab
From Junshi Biosciences
Via GlobeNewswire
News headline image
Junshi Biosciences Announces Approval of the sNDA for Toripalimab for the 1st-Line Treatment of Renal Cancer
From Junshi Biosciences
Via GlobeNewswire
News headline image
Junshi Biosciences Announces 2023 Full Year Financial Results and Provides Corporate Updates
From Junshi Biosciences
Via GlobeNewswire
News headline image
Junshi Biosciences Announces Toripalimab’s NDA Accepted by the Singapore Health Sciences Authority
From Junshi Biosciences
Via GlobeNewswire
News headline image
Junshi Biosciences Announces JAMA Publication of Results from NEOTORCH, a Randomized Phase 3 Trial of Perioperative Toripalimab plus Chemotherapy for Patients with Resectable Non-Small Cell Lung Cancer
From Junshi Biosciences
Via GlobeNewswire
News headline image
Junshi Biosciences Announces Publication of Results from TORCHLIGHT, a Randomized Phase 3 Trial of Toripalimab for the Treatment of Metastatic or Recurrent Triple-negative Breast Cancer in Nature Medicine
From Junshi Biosciences
Via GlobeNewswire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story